Is CVS Health the Ultimate Value Stock to Buy Right Now?

CVS Health is presented as a value opportunity, trading at just under 11x forward earnings while 2025 sales rose 7.8% to a record $402.1 billion and adjusted EPS climbed 24.5% to $6.75. The company guided to 2026 adjusted EPS of $7.00 to $7.20, at least $9 billion in 2026 operating cash flow, and cited a 2.48% Medicare rate increase that could support Aetna margins. Dividend growth remains intact, with the payout up 33% since 2022 and a 3.46% yield.

Analysis

The market is still valuing CVS like a retail pharmacy with insurance attached, when the more durable economics come from owning the patient workflow. The real second-order benefit is that every incremental script, clinic visit, and MA member steered into the CVS ecosystem lowers medical cost trend, which can expand underwriting margin over time and justify a higher multiple than a standalone PBM or insurer.

The Medicare rate reset matters less as a one-quarter earnings bump than as a signal that the earnings revision cycle may be turning up. If Aetna’s margin stabilizes while pharmacy and clinic volumes keep compounding, CVS can convert a flat revenue base into mid-teens EPS growth through mix, utilization, and buyback optionality once leverage is more comfortable. That is the setup that typically rerates a “low-multiple value trap” into a cash-flow compounder.

The contrarian miss is that downside is increasingly tied to execution rather than macro. If management can keep medical ratios from re-accelerating and demonstrate that clinic density improves retention and prescription capture, the market may be forced to re-rate the stock before the next multiple expansion in the sector. The main risk is that one bad utilization cycle or another policy surprise in Medicare Advantage quickly compresses the entire thesis because the stock is still priced for disappointment.

Key Decisions for Investors

• Go long CVS on weakness into the next earnings print, with a 3-6 month horizon; the setup is asymmetric if management confirms stable medical ratios and guided EPS keeps trending toward the high end of the range.
• Sell puts on CVS 10-15% below spot for a 1-2 quarter horizon; the implied downside appears better protected by cash flow and dividend support than the market is pricing.
• Pair trade: long CVS / short a pure-play managed care name with similar Medicare exposure over the next 6-12 months; CVS has more internal cost-control levers and less dependence on third-party provider inflation.
• Consider a covered-call overwrite on an existing CVS position if you own for yield; the stock’s rerating path likely remains gradual, so monetizing elevated implied volatility can improve carry while preserving core upside.
• If CVS closes above prior resistance after earnings, add only on confirmation rather than anticipation; the trade is about multiple expansion through evidence, not just cheapness.